Teva’s sNDA For Bronchospasm Therapy ProAir RespiClick Gets US FDA Approval For Review
Asthma, News
The US Food and Drug Administration (FDA) recently accepted review of the supplemental New Drug Application (sNDA) filed by Teva Pharmaceuticals‘ novel drug formulation Pro Air RespiClick. The therapy is ... Read more